Literature DB >> 8567178

Chemical synthesis and characterization of ShK toxin: a potent potassium channel inhibitor from a sea anemone.

M W Pennington1, M E Byrnes, I Zaydenberg, I Khaytin, J de Chastonay, D S Krafte, R Hill, V M Mahnir, W A Volberg, W Gorczyca.   

Abstract

ShK-toxin, a 35 residue peptide isolated from the sea anemone Stichodactyla helianthus, was synthesized using an Fmoc strategy and successfully folded to the biologically active form containing three intramolecular disulfide bonds. The ability of synthetic ShK toxin to inhibit specific [125I]-dendrotoxin I binding to rat brain membranes slightly exceeded (was more potent than) that of the natural ShK toxin sample, but was comparable with previously reported data for ShK toxin. The peptide toxin inhibited [125I]-charybdotoxin binding to Jurkat T lymphocytes with an IC50 value of 32 pM. In addition, Jurkat T lymphocytes Kv1.3 potassium channels were inhibited with an IC50 value of 133 pM. Owing to their unique structure and high affinity for at least some potassium channels, ShK toxin and related sea anemone potassium channel toxins may become useful molecular probes for investigating potassium channels.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8567178     DOI: 10.1111/j.1399-3011.1995.tb01068.x

Source DB:  PubMed          Journal:  Int J Pept Protein Res        ISSN: 0367-8377


  27 in total

Review 1.  K+ channels as targets for specific immunomodulation.

Authors:  K George Chandy; Heike Wulff; Christine Beeton; Michael Pennington; George A Gutman; Michael D Cahalan
Journal:  Trends Pharmacol Sci       Date:  2004-05       Impact factor: 14.819

2.  Modeling the binding of three toxins to the voltage-gated potassium channel (Kv1.3).

Authors:  Rong Chen; Anna Robinson; Dan Gordon; Shin-Ho Chung
Journal:  Biophys J       Date:  2011-12-07       Impact factor: 4.033

3.  Shaker-related potassium channels in the central medial nucleus of the thalamus are important molecular targets for arousal suppression by volatile general anesthetics.

Authors:  Maria I Lioudyno; Alexandra M Birch; Brian S Tanaka; Yuri Sokolov; Alan L Goldin; K George Chandy; James E Hall; Michael T Alkire
Journal:  J Neurosci       Date:  2013-10-09       Impact factor: 6.167

Review 4.  Computational methods of studying the binding of toxins from venomous animals to biological ion channels: theory and applications.

Authors:  Dan Gordon; Rong Chen; Shin-Ho Chung
Journal:  Physiol Rev       Date:  2013-04       Impact factor: 37.312

Review 5.  Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases.

Authors:  Victor Chi; Michael W Pennington; Raymond S Norton; Eric J Tarcha; Luz M Londono; Brian Sims-Fahey; Sanjeev K Upadhyay; Jonathan T Lakey; Shawn Iadonato; Heike Wulff; Christine Beeton; K George Chandy
Journal:  Toxicon       Date:  2011-08-12       Impact factor: 3.033

6.  Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases.

Authors:  Christine Beeton; Michael W Pennington; Heike Wulff; Satendra Singh; Daniel Nugent; George Crossley; Ilya Khaytin; Peter A Calabresi; Chao-Yin Chen; George A Gutman; K George Chandy
Journal:  Mol Pharmacol       Date:  2005-01-21       Impact factor: 4.436

7.  Reinvestigation of the biological activity of d-allo-ShK protein.

Authors:  Bobo Dang; Sandeep Chhabra; Michael W Pennington; Raymond S Norton; Stephen B H Kent
Journal:  J Biol Chem       Date:  2017-06-08       Impact factor: 5.157

Review 8.  Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases.

Authors:  Christine Beeton; Michael W Pennington; Raymond S Norton
Journal:  Inflamm Allergy Drug Targets       Date:  2011-10

Review 9.  Natural products and ion channel pharmacology.

Authors:  Russell W Teichert; Baldomero M Olivera
Journal:  Future Med Chem       Date:  2010-05       Impact factor: 3.808

Review 10.  The functional network of ion channels in T lymphocytes.

Authors:  Michael D Cahalan; K George Chandy
Journal:  Immunol Rev       Date:  2009-09       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.